Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for LDL-C reduction in treatment-resistant atherosclerotic cardiovascular disease
IRCT20230309057664N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of evolocumab in dyslipidemia and atherosclerotic disease, sponsored by Hamadan University of Medical Sciences. Started Dec 2024; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemiaatherosclerotic disease
Beyond the preview
Go deeper on IRCT20230309057664N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230309057664N1.